Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 19/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 16/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283345 | 0.89 | OPRD1 (0.57) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| Hydrochloric Acid SCHEMBL4279696 | 0.88 | OPRD1 (0.60) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL4284752 | 0.81 | OPRD1 (0.59) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL4277324 | 0.80 | OPRD1 (0.58) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| Hydrochloric Acid SCHEMBL4270071 | 0.80 | OPRD1 (0.55) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL4424814 | 0.80 | OPRD1 (0.58) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| Hydrochloric Acid SCHEMBL4270108 | 0.77 | OPRD1 (0.59) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| Hydrochloric Acid SCHEMBL4274394 | 0.77 | OPRD1 (0.52) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| Lithium Ion SCHEMBL4279346 | 0.76 | OPRD1 (0.57) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| Hydrochloric Acid SCHEMBL4279770 | 0.75 | OPRD1 (0.56) | OPRD1KCNH2OPRK1CYP2D6OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507824-B2 | Spiro(2H-1benzopyran-2,4′-piperidine) derivates as glycine transport inhibitors | N.V. ORGANON (NL) | 2009-03-24 | — | — | US | disclosed |
| EP-1232160-B1 | SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE)DERIVATES AS GLYCINE TRANSPORT INHIBITORS | ORGANON NV (NL) | 2008-06-18 | — | — | EP | disclosed |
| US-20040029904-A1 | Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029904-A1 | Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors | SLC6A7, SLC1A2, SLC6A1 | OPRD1 504/4885KCNH2 277/4885OPRK1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.